What endo patients told a survey

In 2026 researchers finally asked women with endometriosis what GLP-1 medications were doing for them. The answers are interesting, hopeful, and — importantly — not yet proof of anything.

If you have endometriosis, you know the particular exhaustion of being a research afterthought. It takes years to get diagnosed, the treatments on offer are decades old, and most of the excitement in metabolic medicine has sailed right past you. So when a study came out in 2026 that actually asked women with endometriosis about their experience on GLP-1 medications, we read it closely.

It was an international survey — women describing, in their own words, how GLP-1 receptor agonists affected their symptoms, their quality of life, the daily burden of managing the disease, and whether things came back. Survey, we'd underline. Not a trial. But after being left out of the conversation for so long, being asked at all is a small thing that isn't small.

What the women reported

The themes that came through were mostly about the whole person, not a cure: shifts in weight, changes in body image, a sense of personal empowerment, a lighter treatment burden for some. The researchers' careful conclusion was that GLP-1 medicines might have a possible adjunctive role — a supporting one — particularly for women whose endometriosis sits alongside metabolic or inflammatory issues. Adjunctive is the key word. Nobody is claiming these drugs treat the disease.

Being asked at all is a small thing that isn't small.

The biology nobody can fully explain yet

There's a genuinely intriguing thread underneath. Endometriosis is increasingly understood as a full-body inflammatory condition, not just a pelvic one — tangled up with immune signaling and metabolic cross-talk. Older laboratory work found GLP-1 levels were actually lower in the pelvic fluid of women with endometriosis than in women without it. What that means is still an open question. It's a clue, not a conclusion, and we'd be doing you a disservice to pretend otherwise.

Why we're keeping our voice careful

Here's the honest tension. Women with endometriosis have been dismissed for so long that the arrival of anyone studying them feels like validation — and validation is easy to inflate into "this is the answer." It isn't, yet. What we can say is that the research door has finally opened a crack, that early reports from patients are more good than bad, and that the metabolic and inflammatory overlap is real enough to be worth serious study.

What we won't say is that a GLP-1 is a treatment for endometriosis, because it isn't, and because you've been let down enough by people who overpromised. If a GLP-1 is ever part of your picture, it's a decision for you and a clinician who understands both your metabolic health and your endo — not something to take from a survey, or from us.

For the woman still waiting to be studied

We wrote this because you deserve to know what's happening in the research, in plain language, without the hype. That's the same reason we built the comparison — to help you find providers who understand the whole-woman picture, and who won't dismiss the endometriosis half of it. The science is early. Your right to be taken seriously is not.

The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a recommendation, and not a promise of any result. GLP-1 medications are not FDA-approved for and are not a treatment for endometriosis; the research described here is early and largely observational. Please make medical decisions with a licensed clinician who knows your history, not with a website. Selene is editorial — we don't prescribe, sell, or dispense anything.

← More from the Journal